leadf
logo-loader
AIM:FARN OTC:FPHAF

Faron Pharmaceuticals Oy

Receive alerts
Market:
AIM
Market Cap:
£201.58 m
Price
399.50 GBX
Change
-4.31%
52 weeks high
495.00
52 weeks low
216.05

In brief

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is a strong anti-viral and anti-inflammatory agent, currently being tested in several Phase III studies around the world against COVID-19. Faron is based in Turku, Finland.

Snapshot

  • Faron Pharma says study provides 'compelling' evidence cancer drug increases survival in patients with late-stage tumours
  • Faron Pharmaceuticals enjoys momentum as COVID-19 drug candidate gets green light for late-stage trials
  • Faron Pharma: City broker provides its commentary on Covid trial
  • Faron Pharmaceuticals' update on balance sheet, Traumakine and Bexmarilimab